{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:50:08Z","timestamp":1793213408434,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate the clinical benefit and safety of trilaciclib in solid-tumor patients receiving chemotherapy and to inform clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA guidelines and registered at PROSPERO (CRD420251053232), we searched PubMed, Embase and two other databases from inception to June 2025. Six randomized controlled trials enrolling 726 patients were included. Meta-analyses were performed with Review Manager 5.4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Trilaciclib significantly reduced the incidence of severe neutropenia (SN) and febrile neutropenia (FN), shortened SN duration, and decreased the need for erythropoiesis-stimulating agents (ESAs), granulocyte colony-stimulating factor (G-CSF) and red-blood-cell (RBC) transfusions while lowering anemia rates. These benefits were not accompanied by increased risks of nausea, vomiting or fatigue. Progression-free survival (PFS) was significantly prolonged, whereas overall survival (OS) remained unchanged; patients aged \u226565 years and those enrolled in U.S. trials derived the greatest benefit. Limitations include the small number of RCTs, heterogeneous chemotherapy regimens, potential publication bias and short follow-up in some studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Trilaciclib effectively prevents chemotherapy-induced myelosuppression in solid-tumor patients and can guide clinical use, but further well-designed studies are warranted to consolidate its efficacy and safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420251053232URL.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1754502","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:27:49Z","timestamp":1775636869000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Trilaciclib for prophylaxis of chemotherapy-induced myelosuppression in solid tumor patients: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Ting","family":"Yang","sequence":"first","affiliation":[{"name":"College of Pharmacy, Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Peking University Cancer Hospital (Inner Mongolia Campus)\/Affiliated Cancer Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking University Cancer Hospital (Inner Mongolia Campus)\/Affiliated Cancer Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Surgery of Bone and Soft Tissue Tumors, Peking University Cancer Hospital (Inner Mongolia Campus)\/Affiliated Cancer Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benben","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University Cancer Hospital (Inner Mongolia Campus)\/Affiliated Cancer Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.3390\/ijms25094807","article-title":"Balancing benefits and risks: a literature review on hypersensitivity reactions to human G-CSF (granulocyte colony-stimulating factor)","volume":"25","author":"Bumb\u0103cea","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2217\/fon-2023-0513","article-title":"The impact of myelosuppression on quality of life of patients treated with chemotherapy","volume":"20","author":"Crawford","year":"2024","journal-title":"Future Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/ijc.33453","article-title":"Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive\u2010stage small cell lung cancer: a multicentre, randomised, double\u2010blind, placebo\u2010controlled phase II trial","volume":"148","author":"Daniel","year":"2021","journal-title":"Int. J. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.21037\/tlcr-2025-67","article-title":"Myelopreservation effect of trilaciclib in extensive-stage small cell lung cancer (ES-SCLC): a systematic review and meta-analysis with trial sequential analysis of randomized clinical trials","volume":"14","author":"Ding","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.53876\/001c.38340","article-title":"Trilaciclib use and chemotherapy-induced myelosuppression among patients with ES- SCLC in US community oncology settings","volume":"18","author":"Goldschmidt","year":"2022","journal-title":"Int. J. Cancer Care Deliv."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1007\/s12325-023-02601-2","article-title":"Real-world outcomes of trilaciclib among patients with extensive-stage small cell lung cancer receiving chemotherapy","volume":"40","author":"Goldschmidt","year":"2023","journal-title":"Adv. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11060-020-03483-y","article-title":"Immune suppression in gliomas","volume":"151","author":"Grabowski","year":"2021","journal-title":"J. Neuro-Oncology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"10020","DOI":"10.1002\/cam4.5738","article-title":"Burden of chemotherapy\u2010induced myelosuppression among patients with extensive\u2010stage small cell lung cancer: a retrospective study from community oncology practices","volume":"12","author":"Hart","year":"2023","journal-title":"Cancer Med."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3986","article-title":"Transient CDK4\/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion","volume":"9","author":"He","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B11","first-page":"1752","article-title":"Red blood cell storage lesion-induced adverse effects: more smoke; is there fire?","volume-title":"Anesth. Analg.","author":"Hod","year":"2017"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.2147\/CMAR.S313045","article-title":"Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: pooled results from three phase 2, randomized, double-blind, placebo-controlled studies","volume":"13","author":"Hussein","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s40261-022-01179-x","article-title":"Pharmacokinetic drug\u2013drug interaction studies between trilaciclib and midazolam, metformin, rifampin, itraconazole, and topotecan in healthy volunteers and patients with extensive-stage small-cell lung cancer","volume":"42","author":"Li","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/bcp.15549","article-title":"Population pharmacokinetics and exposure\u2013response of trilaciclib in extensive\u2010stage small cell lung cancer and triple\u2010negative breast cancer","volume":"89","author":"Li","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"856","DOI":"10.20892\/j.issn.2095-3941.2023.0281","article-title":"Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors","volume":"20","author":"Liu","year":"2023","journal-title":"Cancer Biol. and Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12288-019-01170-1","article-title":"Updates on novel erythropoiesis-stimulating agents: clinical and molecular approach","volume":"36","author":"Moradi","year":"2020","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"B17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000492629","article-title":"An international registry of granulocyte transfusions","volume":"45","author":"Pagano","year":"2018","journal-title":"Transfus. Med. Hemotherapy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1157251","DOI":"10.3389\/fphar.2023.1157251","article-title":"The efficacy and safety of trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Qiu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e17835","DOI":"10.7759\/cureus.17835","article-title":"Efficacy and cardiovascular adverse effects of erythropoiesis stimulating agents in the treatment of cancer-related anemia: a systematic review of randomized controlled trials","volume":"13","author":"Rao","year":"2021","journal-title":"Cureus"},{"key":"B20","first-page":"719","article-title":"Transfusion of blood and blood products: indications and complications","volume":"83","author":"Sharma","year":"2011","journal-title":"Am. Fam. Physician"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s00210-023-02781-2","article-title":"Effects of chemotherapy on the immune system: implications for cancer treatment and patient outcomes","volume":"397","author":"Sharma","year":"2024","journal-title":"Naunyn-Schmiedeberg\u2019s Archives Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1136\/jitc-2021-sitc2021.339","article-title":"339 immune profiling to investigate improved survival in patients with metastatic triple-negative breast cancer receiving trilaciclib prior to chemotherapy","volume":"9","author":"Stevens","year":"2021","journal-title":"BMJ Spec. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10549-023-07009-8","article-title":"Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer","volume":"201","author":"Tan","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1343239","DOI":"10.3389\/fonc.2024.1343239","article-title":"Myelopreservation with trilaciclib in recurrent advanced ovarian cancer: a case report","volume":"14","author":"Tan","year":"2024","journal-title":"Front. Oncol."},{"key":"B25","volume-title":"Analysis of myelosuppression in post-chemotherapy breast cancer patients (A study at division of hematology and medical oncology Airlangga university hospital)","author":"Utomo","year":"2024"},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1227528","DOI":"10.3389\/fphar.2023.1227528","article-title":"Analysis of adverse drug reactions\/events of cancer chemotherapy and the potential mechanism of Danggui Buxue decoction against bone marrow suppression induced by chemotherapy","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2202058","DOI":"10.1002\/advs.202202058","article-title":"Myelosuppression alleviation and hematopoietic regeneration by tetrahedral\u2010framework nucleic\u2010acid nanostructures functionalized with osteogenic growth peptide","volume":"9","author":"Zhang","year":"2022","journal-title":"Adv. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1754502\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:27:51Z","timestamp":1775636871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1754502\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":28,"alternative-id":["10.3389\/fphar.2026.1754502"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1754502","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"article-number":"1754502"}}